Condition: Acute Respiratory Failure · Hypercoagulability · Fibrinolysis Shutdown · Sponsor: South West Sydney Local Health District
Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.
This description comes directly from the study's public registry record.
Anders Aneman · +61 427915693 · Anders.Aneman@health.nsw.gov.au
Lucy Coupland · +61 419723330 · l.coupland@unsw.edu.au
Always discuss trial participation with your own doctor first.
| Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District | Liverpool, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05540834